DIGALACTOSYLCERAMIDE IS THE RECEPTOR FOR STAPHYLOCOCCAL-ENTEROTOXIN-B IN HUMAN KIDNEY PROXIMAL TUBULAR CELLS

We have characterized a glycosphingolipid (GSL) receptor for Staphylococcus enterotoxin-B (SEB) in cultured human kidney proximal tubular (PT) cells. Solid-phase binding of [I-125]SEB to the GSL receptor was concentration dependent and was not displaceable by two structurally related toxins, such as staphylococcal enterotoxin-A and toxic shock syndrome toxin-1. Rat kidney cells did not bind [I-125]SEB. However, when the rat kidney cells were pre-incubated with digalactosylceramide, there was a concentration-dependent binding of [I-125]SEB. Trimethylsilyl derivatization of methyl glycosides, followed by gas-liquid chromatography-mass spectrometry (GC-MS), revealed that galactose was the major sugar component of this putative receptor GSL. The sphingosines present in this GSL were d18:2, d22:2 and d23:0; the fatty acids present were palmitate, oleate and stearate. Permethylation of alditol acetates and GC-MS revealed two predominant sugars, namely 2, 3, 4 and 6 tetramethylgalactital and 2, 3 and 6 trimethylgalactital. The GSL receptor for SEB was sensitive to alpha-galactosidase, and resistant to beta-galactosidase and beta-glucosidase. Taken together, our studies reveal that the tentative structure of the receptor for SEE in human kidney PT cells is CerGal alpha 1-->4Gal. In summary, we have identified a GSL as one of the binding sites of SEB, a food-bone toxin. We believe that our funding may open up rational approaches for the therapy of SEB-induced glycopathology in man.